We develop highly sensitive detection methods for the early detection of disease-specific aggregates<\/span>. These enable faster and more precise diagnosis and therefore potentially earlier therapeutic intervention. <\/p>\n<\/div><\/div><\/div><\/div><\/div>Innovative technologies<\/h2><\/div><\/div><\/div><\/i><\/div><\/div>SIFT technology<\/h3><\/div>We use single-particle fluorescence technology (SIFT) to identify promising drug candidates. This highly sensitive method detects individual fluorescent molecules and allows protein-protein interactions to be analyzed at the molecular level. <\/p>\n<\/div><\/div><\/div><\/div><\/div>
Our diagnostic development program<\/h2><\/div><\/div><\/div><\/i><\/div><\/div>SAA<\/span> technology<\/h3><\/div>Aggregated alpha-synuclein protein can be detected using an SAA (Seed Amplification Assay). Very small amounts of aggregated alpha-synuclein accumulate in the spinal fluid of patients – in a concentration that cannot be measured by conventional means. With the help of an SAA, these protein clumps in the patient sample are “fed” in the laboratory by adding synthetically produced building blocks. The building blocks bind to the patient’s own alpha-synuclein clumps and artificially multiply them. As a result, the patient’s disease-causing proteins are multiplied millions of times and can be detected by binding a specific dye. This is the only way to detect the Parkinson’s disease process directly in the cerebrospinal fluid. <\/p>\n<\/div><\/div><\/div>
<\/i><\/div><\/div>PET tracer<\/h3><\/div>We are working on the development of synuclein-specific PET tracers for precise in vivo diagnostics. This imaging technology could revolutionize the early detection and monitoring of synucleinopathies. A PET tracer is a weakly radioactively labeled substance that is administered to the patient shortly before he or she “enters the tube”, i.e. the scanner, and binds to the disease-causing clumps. The computer localizes the PET tracer and the alpha-synuclein deposits become visible to the doctor. <\/p>\n<\/div><\/div><\/div><\/div><\/div>
<\/div>
MODAG cooperates<\/span> with<\/span><\/span> <\/span> leading research institutions in the USA and Europe<\/span> in order to utilize synergies and drive innovation<\/span>.<\/h3><\/div><\/div><\/div><\/div><\/div>Our most important partners include<\/h3><\/div>![\"Logo](\"https:\/\/www.modag.net\/wp-content\/uploads\/2024\/12\/LMU.png\" "\\"LMU\\"")
<\/span><\/div>Ludwig-Maximilians-University Munich<\/strong><\/p>\n One of the most renowned universities in Germany, which supports us in basic research and the development of new therapeutic approaches.<\/p>\n<\/div><\/div><\/div>
![\"Logo](\"https:\/\/www.modag.net\/wp-content\/uploads\/2024\/12\/MAX-PLANCK.png\" "\\"MAX")
<\/span><\/div>Max Planck Institute for Biophysical Chemistry G\u00f6ttingen<\/b><\/span><\/p>\n <\/b><\/span>This institute contributes its expertise in structural biology and NMR spectroscopy in order to understand the molecular mechanisms of our active ingredients.<\/p>\n<\/div><\/div><\/div>![\"Logo\"](\"https:\/\/www.modag.net\/wp-content\/uploads\/2025\/01\/10051_uni_tuebingen_logo_300px_u.png\" "\\"10051_uni_tuebingen_logo_300px_u\\"")
<\/span><\/div>Eberhard Karls University of T\u00fcbingen<\/b><\/p>\n
This renowned research institution supports us with its expertise in clinical neurology and biomarker research, particularly in the development of alpha-synuclein PET tracers for innovative diagnostic procedures in Parkinson’s and MSA.<\/p>\n<\/div><\/div><\/div>
![\"Logo](\"https:\/\/www.modag.net\/wp-content\/uploads\/2024\/12\/Michael-J.-Fox-Foundation.png\" "\\"Michael")
<\/span><\/div>Michael J. Fox Foundation for Parkinson’s Research
<\/b><\/p>\n
Through this cooperation, we receive support in the financing and implementation of research projects to fight Parkinson’s disease.<\/p>\n<\/div><\/div><\/div>
![\"logo\"](\"https:\/\/www.modag.net\/wp-content\/uploads\/2024\/12\/Bayerische-Patentallianz-sw.png\" "\\"Bayerische")
<\/span><\/div>Bavarian Patent Alliance GmbH<\/b><\/p>\n
As the central patent exploitation agency, it plays an important role in securing and commercializing our technologies.<\/p>\n<\/div><\/div><\/div><\/div>
<\/div><\/div><\/div><\/div><\/div>
<\/div><\/div>
<\/div><\/div><\/div><\/div><\/div><\/div><\/div>
Our current<\/span> research projects<\/span><\/h2><\/div>As part of our ongoing efforts to develop innovative solutions for neurodegenerative diseases, MODAG is focusing on several promising research projects that are in various stages of development.<\/p>\n<\/div><\/div><\/div>
Our work on emrusolmin (anle138b)<\/h3><\/div>Our lead candidate for MSA is currently in clinical phase 2. Preclinical studies showed a significant reduction in alpha-synuclein aggregation and an improvement in motor symptoms in animal models.<\/p>\n<\/div>